ArticleMarine biotechnology (New York, N.Y.)2026
Endophytic Fungi Associated with Seaweeds as Potential Producers of Antimicrobial Compounds.
Article in Marine biotechnology (New York, N.Y.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The urgent need for new molecules capable of targeting multidrug-resistant microorganisms has redirected bioprospecting efforts toward less explored marine environments and their associated communities, such as marine mycobiota. This study aimed to evaluate the antimicrobial potential of endophytic fungi isolated from various seaweed species and infer the mechanisms of action and chemical profile of most potent fungal extracts. Simultaneously, it intended to contribute to a better understanding of ecological requirements of each fungal species. Thirty-one ascomycetous fungi were recovered from the seaweed hosts, with a higher representation of the genera Aspergillus and Penicillium. Only two fungal species revealed notable antimicrobial abilities: Penicillium rubens synthesised extracts with pronounced antibacterial effects against Escherichia coli, Pseudomonas aeruginosa and Staphylococcus aureus, while extracts of Penicillium brevicompactum inhibited the growth of Candida albicans. Although similar activities have been described in a few previous studies, this is the first report of a markedly inhibitory effect against a pathogenic yeast demonstrated by P. brevicompactum. Moreover, the mechanisms of action underlying these activities were explored for the first time in this study. Specifically, the antimicrobial activities demonstrated by fungal extracts were likely mediated by membrane potential imbalance and DNA damage, associated with the presence of L-norvaline and formylphosphonate. Despite the overall consistency of the results, slight to pronounced differences were also observed in the antibacterial activities and mechanisms of action of the extracts from P. rubens strains. These findings support the hypothesis that marine fungal species possess, and express distinct metabolic profiles shaped by micro- and/or macro-environmental factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.